

CITATION REPORT

List of articles citing

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology

DOI: 10.1007/s40264-018-0772-x
Drug Safety, 2019, 42, 181-198.

Source: <https://exaly.com/paper-pdf/74636514/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
50	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. <i>Biomolecules</i> , 2019 , 9,	5.9	39
49	Safety of Novel Targeted Therapies in Oncology. <i>Drug Safety</i> , 2019 , 42, 157-158	5.1	1
48	Epidermal growth factor receptor role in pancreatic cancer. 2019 , 295-324		1
47	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 337-345	5.2	17
46	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <i>Current Heart Failure Reports</i> , 2020 , 17, 365-383	2.8	13
45	Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study. <i>ESMO Open</i> , 2020 , 5, e000864	6	4
44	In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. <i>Molecules</i> , 2020 , 25,	4.8	9
43	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1907-1918	8.9	36
42	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020 , 11, 4607	17.4	31
41	1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells. <i>Cell Death and Disease</i> , 2020 , 11, 670	9.8	6
40	Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 909-919	2.8	10
39	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. <i>Scientific Reports</i> , 2020 , 10, 4803	4.9	22
38	A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 181	3.5	7
37	On precision dosing of oral small molecule drugs in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 263-270	3.8	0
36	Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease. <i>Frontiers in Pharmacology</i> , 2020 , 11, 598910	5.6	3
35	GI Toxicities from Cancer Therapy. 2021 , 341-379		
34	Olmotinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. <i>Cancer</i> , 2021 , 127, 1407-1416	6.4	8

33	Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI. <i>Frontiers in Oncology</i> , 2020 , 10, 573512	5.3	0
32	Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103305	7	2
31	Purchase of prophylactic topical corticosteroids is associated with improved survival in NSCLCs treated with EGFR TKI: real-world cohort study. <i>Acta Oncologica</i> , 2021 , 60, 1100-1105	3.2	
30	Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors. <i>Metabolites</i> , 2021 , 11,	5.6	0
29	CDK 4/6 inhibitor induced lung injury: a case report and review of literature. <i>Ecancermedicalscience</i> , 2021 , 15, 1245	2.7	2
28	Protein Kinase Inhibitors - Selectivity or Toxicity?.		0
27	Discovery of a novel series of substituted quinolines acting as anticancer agents and selective EGFR blocker: Molecular docking study. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021 , 44, 128118	2.9	3
26	Cardiac Safety Assessment of Lazertinib: Findings From Patients With Mutation-Positive Advanced NSCLC and Preclinical Studies. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100224	1.4	0
25	Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 739843	5.6	0
24	Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression. <i>Pharmacology & Therapeutics</i> , 2021 , 107992	13.9	2
23	GI Toxicities from Cancer Therapy. 2020 , 1-39		
22	Design and synthesis of some novel pyridothienopyrimidine derivatives and their biological evaluation as antimicrobial and anticancer agents targeting EGFR enzyme. <i>Arabian Journal of Chemistry</i> , 2022 , 15, 103751	5.9	0
21	Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.. <i>Frontiers in Oncology</i> , 2022 , 12, 804212	5.3	1
20	Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells.. <i>Cell Death Discovery</i> , 2022 , 8, 122	6.9	0
19	Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.. <i>Breast</i> , 2022 , 62, 162-169	3.6	1
18	NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.. <i>Cells</i> , 2021 , 10,	7.9	4
17	Image_1.tif. 2021 ,		
16	Table_1.docx. 2021 ,		

15	Association of White Matter Hyperintensities with Long-Term EGFR-TKI Treatment and Risk Factors. <i>SSRN Electronic Journal</i> ,	1	
14	Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. <i>Current Medical Research and Opinion</i> , 1-20	2.5	
13	Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. <i>Clinical Medicine Insights: Oncology</i> , 2022 , 16, 117955492211032	1.8	○
12	Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	○
11	Discovery of novel 4-arylamino-quinazoline derivatives as EGFR L858R/T790M inhibitors with the potential to inhibit the non-small cell lung cancers. <i>Bioorganic Chemistry</i> , 2022 , 127, 105994	5.1	○
10	Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report. 2022 , 36, 1		○
9	The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI Therapy.		○
8	Identifying the Patterns of Adverse Drug Responses of Cetuximab. 2022 , 32, 226-237		○
7	Molecular targeted therapy for anticancer treatment.	1	
6	EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. 2022 , 58, 1645		○
5	Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. 2023 , 175, 112-120		○
4	Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats. 2023 , 30, 103522		○
3	Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches. 1-14		○
2	Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study. 2023 , 23,		○
1	New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.		○